|Articles|January 1, 1997

Managing Hypercholesterolemia and Coronary Heart Disease
Volume 3
Issue 1 Suppl

Pharmacoeconomics: The Cost Effectiveness of Lipid Management

Download PDF: Pharmacoeconomics: The Cost Effectiveness of Lipid Management

Articles in this issue

over 29 years ago

Article

MCO Decisions and Solutions

over 29 years ago

Article

The Importance of Lipid Lowering and Other Risk Reduction Therapies

over 29 years ago

Article

Matching Risks to Interventions: When to Treat, How to Treat

over 29 years ago

Article

CME Quiz

over 29 years ago

Article

Bibliography

over 29 years ago

Article

Participants

over 29 years ago

Article

Goals and Objectives

over 29 years ago

Article

Introduction

over 29 years ago

Article

Clinical Study Outcomes and the Benefits of Treating Hypercholesterolemia

over 29 years ago

Article

Goals for Patient Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Pharmacoeconomics: The Cost Effectiveness of Lipid Management

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

Managing the Tafasitamab Triplet: Safety Profile, Adverse Events, and Clinical Implications from inMIND